Targeted therapies: the answer to individualized treatment?
Lisa Hutchinson
This article has no abstract so we have provided the first paragraph of the full text.
Much excitement and optimism has been generated by the advent of targeted therapies for treating cancer. Notable examples include imatinib for treating chronic myelogenous leukemia and gastrointestinal tumors, gefitinib and erlotinib for non-small-cell lung cancers, trastuzumab in women with breast cancer who overexpress HER2, and sunitinib and sorafinib for renal cancer. Undoubtedly, these agents have contributed significantly to the armamentarium of approaches employed to treat and—in the adjuvant setting—cure cancer. Nonetheless, while tools and other technological advances developed in the past decades have fostered bed-to-benchside progress in clinical oncology, our understanding of the molecular carcinogenic process and the ability to test agents in multiple complex disease subtypes and settings, is, by comparison, still in its infancy.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.